Prexa Pharmaceuticals
Prexa Pharmaceuticals develops small molecule monoamine reuptake inhibitors as a treatment for ADHD, depression and Parkinson’s disease.
Employees
Enterprise value
$28—42m
| Date | Investors | Amount | Round |
|---|---|---|---|
$7.0m | Series B | ||
| Total Funding | 000k | ||
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads